Clinical Trial: NCT05786430
Lazertinib+Pemetrexed/Carboplatin in Patients With EGFR Sensitizing Mutation Positive Recurrent or Metastatic Non-Small Cell Lung Cancer Failed to Prior Lazertinib
Status:
COMPLETEDPhase:
Phase 2| Lead Sponsor: | Yonsei University |
| Information Provided By: | Yonsei University |
| Last Update Posted: | 2026-10-07 |
Study Overview
Brief Summary
This trial is Phase II Trial of Lazertinib+Pemetrexed/Carboplatin in Patients with EGFR Sensitizing Mutation Positive Recurrent or Metastatic Non-Small Cell Lung Cancer Failed to prior lazertinib.
Official Title
Phase II Trial of Lazertinib+Pemetrexed/Carboplatin in Patients With EGFR Sensitizing Mutation Positive Recurrent or Metastatic Non-Small Cell Lung Cancer Failed to Prior Lazertinib (LUCAS)
Conditions
Non-small Cell Lung Cancer
Intervention / Treatment
- Drug: Lazertinib/Pemetrexed/Carboplatin
Other Study ID Numbers
- 4-2022-1142
Start Date (Actual)
2023-04-07
Primary Completion Date (Actual)
2026-08-23
Study Completion Date (Actual)
2026-08-23
Enrollment (Actual)
65
Study Type
Interventional
Phase
Phase 2
| Lead Sponsor: | Yonsei University |
| Information Provided By: | Yonsei University |
| Last Update Posted: | 2026-10-07 |
Study Overview
Brief Summary
This trial is Phase II Trial of Lazertinib+Pemetrexed/Carboplatin in Patients with EGFR Sensitizing Mutation Positive Recurrent or Metastatic Non-Small Cell Lung Cancer Failed to prior lazertinib.
Official Title
Phase II Trial of Lazertinib+Pemetrexed/Carboplatin in Patients With EGFR Sensitizing Mutation Positive Recurrent or Metastatic Non-Small Cell Lung Cancer Failed to Prior Lazertinib (LUCAS)
Conditions
Non-small Cell Lung Cancer
Intervention / Treatment
- Drug: Lazertinib/Pemetrexed/Carboplatin
Other Study ID Numbers
- 4-2022-1142
Start Date (Actual)
2023-04-07
Primary Completion Date (Actual)
2026-08-23
Study Completion Date (Actual)
2026-08-23
Enrollment (Actual)
65
Study Type
Interventional
Phase
Phase 2